Literature DB >> 17530640

Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression.

Nicole S L Goh1, Srihari Veeraraghavan, Sujal R Desai, Derek Cramer, David M Hansell, Christopher P Denton, Carol M Black, Roland M du Bois, Athol U Wells.   

Abstract

OBJECTIVE: To evaluate the prognostic value of bronchoalveolar lavage (BAL) cellular profiles in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
METHODS: BAL cellularity was examined in relation to mortality (n = 141), serial pulmonary function findings (n = 134), and "progression-free survival" (n = 134), by proportional hazards analysis. Baseline severity was quantified according to the extent of disease on high-resolution computed tomography, the diffusing capacity for carbon monoxide, and the presence or absence of pulmonary hypertension. Mortality was subclassified into overall mortality (during 10 years of followup), early mortality (occurring within 2 years of presentation), and late mortality (occurring 2-10 years after presentation).
RESULTS: Overall mortality was associated with neutrophilia on BAL (hazard ratio 2.23 [95% confidence interval 1.20-4.14], P = 0.01), but this effect was lost when disease severity was taken into account. Early mortality was associated with neutrophilia on BAL (hazard ratio 8.40 [95% confidence interval 1.91-36.95], P = 0.005), independent of disease severity. Late mortality was not associated with neutrophilia on BAL. The presence of neutrophilia on BAL was not associated with time to decline in pulmonary function or progression-free survival. Neither eosinophilia nor lymphocytosis on BAL was associated with mortality, rapidity of functional deterioration, or progression-free survival. These findings were unaltered when treatment status was taken into account.
CONCLUSION: BAL findings provide only limited prognostic information in SSc-ILD. Neutrophilia on BAL is linked to early mortality, but BAL findings are not linked to long-term survival or the rapidity of progression of lung disease. The usefulness of BAL to define alveolitis in SSc is questionable.

Entities:  

Mesh:

Year:  2007        PMID: 17530640     DOI: 10.1002/art.22696

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  35 in total

1.  Cyclophosphamide responsive interstitial lung disease in "overlap syndrome": a clinical pathology conference held by the division of rheumatology at the hospital for special surgery.

Authors:  Elizabeth Schulman; Kun Chen; Gregory Saboeiro; Abraham Sanders; Kyriakos Kirou; Robert F Spiera; Anne R Bass; Doruk Erkan
Journal:  HSS J       Date:  2010-10-26

2.  Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design.

Authors:  Dinesh Khanna; James R Seibold; Athol Wells; Oliver Distler; Yannick Allanore; Chris Denton; Daniel E Furst
Journal:  Curr Rheumatol Rev       Date:  2010-05-01

Review 3.  Old medications and new targeted therapies in systemic sclerosis.

Authors:  Vivek Nagaraja; Christopher P Denton; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2014-07-26       Impact factor: 7.580

Review 4.  Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.

Authors:  Elizabeth R Volkmann; Donald P Tashkin
Journal:  Ann Am Thorac Soc       Date:  2016-11

5.  Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.

Authors:  Julie Morisset; Eric Vittinghoff; Brett M Elicker; Xiaowen Hu; Stephanie Le; Jay H Ryu; Kirk D Jones; Anna Haemel; Jeffrey A Golden; Francesco Boin; Brett Ley; Paul J Wolters; Talmadge E King; Harold R Collard; Joyce S Lee
Journal:  Chest       Date:  2017-06-16       Impact factor: 9.410

6.  Induced sputum as a method for detection of systemic sclerosis-related interstitial lung disease.

Authors:  Neslihan Yilmaz; Yasin Abul; Muge Bicakcigil; Pejman Golabi; Cigdem Celikel; Sait Karakurt; Sule Yavuz
Journal:  Rheumatol Int       Date:  2011-03-30       Impact factor: 2.631

7.  Bronchoalveolar lavage in systemic sclerosis with lung involvement: role and correlations with functional, radiological and scintigraphic parameters.

Authors:  Stefania Volpinari; Renato La Corte; Stefano Bighi; Franco Ravenna; Napoleone Prandini; Andrea Lo Monaco; Francesco Trotta
Journal:  Rheumatol Int       Date:  2010-03-30       Impact factor: 2.631

Review 8.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01

Review 9.  [Interstitial lung disease in collagen vascular diseases. Diagnostic and therapeutic implications of non-specific interstitial pneumonia].

Authors:  A Schnabel; M Reuter
Journal:  Z Rheumatol       Date:  2009-10       Impact factor: 1.372

10.  Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients.

Authors:  Katrin Schmidt; Lorena Martinez-Gamboa; Susan Meier; Christian Witt; Christian Meisel; Leif G Hanitsch; Mike O Becker; Doerte Huscher; Gerd R Burmester; Gabriela Riemekasten
Journal:  Arthritis Res Ther       Date:  2009-07-17       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.